Breakfast: Greek Yogurt Bowl 1 cup Greek yogurt (unsweetened) 150 calories, 20g protein cup mixed berries 20 calories, 0g protein 1 tablespoon chia seeds 58 calories, 2g protein 1 tablespoon honey 64 calories, 0g protein Total: 292 calories, 22g protein Lunch: Chicken Salad 3 oz grilled chicken breast 140 calories, 26g protein 2 cups mixed greens 10 calories, 1g protein cup cherry tomatoes 15 calories, 1g protein bell pepper, sliced 12 calories, 0g protein 1 tablespoon olive oil (for dressing) 119 calories, 0g protein 1 tablespoon balsamic vinegar 14 calories, 0g protein Total: 310 calories, 28g protein Snack: Cottage Cheese & Veggies cup low-fat cottage cheese 90 calories, 11g protein bell pepper (sliced) 12 calories, 0g protein cup cherry tomatoes 15 calories, 1g protein Total: 117 calories, 12g protein Dinner: Grilled Chicken Salad 4 oz grilled chicken breast 187 calories, 35g protein 2 cups mixed greens 10 calories, 1g protein cup cherry tomatoes 15 calories, 1g protein bell pepper, sliced 12 calories, 0g protein 1 tablespoon olive oil (for dressing) 119 calories, 0g protein 1 tablespoon balsamic vinegar 14 calories, 0g protein Total: 357 calories, 37g protein Evening Snack: Greek Yogurt & Cottage Cheese cup Greek yogurt (unsweetened) 70 calories, 10g protein cup low-fat cottage cheese 45 calories, 6g protein Total: 115 calories, 16g protein Daily Total: Calories: 1,500 Protein: 100g This meal plan offers a balanced mix of lean protein sources, healthy fats, and fiber-rich vegetables while meeting your target calorie and protein goals

Lustig RH, Schmidt LA, Brindis CD: Public health: The toxic truth about sugar
Researchers focusing specifically on Ipamorelin may reference the Ipamorelin Peptide for single-agent applications in controlled laboratory settings
Randomized Clin Trial Diabetes Care 41(2):258266 Ahrn B, Masmiquel L, Kumar H, Sargin M, Karsbl JD, Jacobsen SH, Chow F (2017) Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial